AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04910763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Increasing strength and fitness and thereby influencing hormones and perceptions involved in appetite regulation.
Study NCT03611322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide, 0.25 mg
Description: Semaglutide will be administered subcutaneously (s.c., under the skin) on day 1 and 8 in the morning after an overnight fast of at least 8 hours
Study NCT03611322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide, 0.25 mg
Description: Semaglutide will be administered subcutaneously (s.c., under the skin) on day 1 and 8 in the morning after an overnight fast of at least 8 hours
Study NCT03611322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide, 0.5 mg
Description: Semaglutide will be administered s.c. (under the skin) on day 15 and 22 in the morning after an overnight fast of at least 8 hours
Study NCT03611322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide, 0.5 mg
Description: Semaglutide will be administered s.c. (under the skin) on day 15 and 22 in the morning after an overnight fast of at least 8 hours
Study NCT03611322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide, 1.0 mg
Description: Semaglutide will be administered s.c. (under the skin) on day 29 in the morning after an overnight fast of at least 8 hours
Study NCT03611322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide, 1.0 mg
Description: Semaglutide will be administered s.c. (under the skin) on day 29 in the morning after an overnight fast of at least 8 hours
Study NCT03611322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DV3372
Description: DV3372 device will be used for administration of semaglutide
Study NCT03611322 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PDS290 pen-injector
Description: PDS290 pen-injector will be used for administration of semaglutide
Study NCT01560897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral C13
Description: Ingestion of C13 and follow up of the ureogenesis
Study NCT00256087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Lactobacillus
Study NCT03752983 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood samples
Description: blood samples
Study NCT05045131 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left atrial combined pulmonary vein isolation and posterior wall isolation
Study NCT03649113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sclerotherapy arm
Description: The liver mass will be punctured under guidance of ultrasonography with a 20- or 22-gauge Chiba needle. Contrast medium will be injected under fluoroscopy guidance to assess any possible communication with the biliary tree and to evaluate the amount of sclerosing agent which could be safely injected. Then, the mixture of Bleomycin (Bleocin-S; Korea United Pharm Inc., South Korea) and Lipiodol (Ultra-Fluid, Guerbet, France) will be slowly injected under continuous guidance of fluoroscopy. No more than 45 units of Bleomycin and 15 cc of Lipiodol will be injected in a single session.
Study NCT01086982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide acetate LAR
Description: 30 mg, single dose
Study NCT01086982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sandostatin LAR ® (octreotide acetate LAR) 30 MG
Description: 30 mg, single dose
Study NCT02634541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Biologic drug
Study NCT02634541 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PET/CT imaging
Description: PET/CT imaging
Study NCT02634541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET/CT imaging
Description: PET/CT imaging
Study NCT02578589 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plica resection vs conservative treatment
Description: Plica resection vs conservative treatment
Study NCT02398617 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Decision Making Intervention
Description: At their regularly scheduled admission follow-up visit with seven days of discharge, participants will be asked to bring their medical decision maker and participate in a semi-structured supplemental palliative care/education session facilitated by a heart failure nurse practitioner trained in palliative care discussions. Domains included in the intervention will include disease literacy and understanding, goals of care, legal issues for patients with terminal illness, symptom management, health-related quality of life, caregiver burden, patient autonomy, healthcare utilization, and establishment of end-of-life plans.
Study NCT02531152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Study NCT02531152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR366234
Study NCT04177355 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by IM injection
Study NCT01939171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Study NCT00256087 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lactose Powder
Study NCT01594138 — intervention group
Intervention type: OTHER
Intervention: Standardized questionnaires and a ubiquitous questionnaire
Description: Columbia Suicide Severity Rating Scale, Suicidal Ideation Questionnaire,Peabody Caregiver Background Form,CCHMC Suicide History Form,and ubiquitous questionnaire(UQ ver.2011)
Study NCT04177355 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3M-052-AF
Description: Administered by IM injection
Study NCT02257164 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve block
Description: 2 mg/ml
Study NCT02257164 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: obturator nerve block
Study NCT02257164 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraarticular injection
Study NCT00720421 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AZD7325
Description: AZD7325 10 mg oral 2 capsules
Study NCT00720421 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AZD7325
Description: AZD7325 1 mg oral 2 capsules
Study NCT03472755 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: The posterolateral approach
Description: The posterolateral approach was used for implantation among patients in lateral position. This approach goes through the gluteus maximus, the piriformis and superior gemeli muscles are detached and later reattached to bone
Study NCT03472755 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Direct anterior technique
Description: patients were fixed in a supine position, a small entry incision was made in the vessel free interval between the tensor fasciae latae and the sartorius muscles and the prosthesis socket were put in place. Via a second dorsal incision, after releasing the external rotators, the prosthesis stem and ball were implanted and the two parts of the prosthesis were attached
Study NCT04650386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial support determined by adaptive treatment algorithm
Description: Participants assigned to the adaptive intervention condition will be scheduled for buprenorphine medication management appointments according to the clinic protocol described above for TAU. The adjunctive psychosocial treatment that participants in this condition receive are (1) CBT delivered by behavioral health specialists and/or (2) peer support delivered by certified recovery specialist. The active intervention period will span 3 months post-study entry. Participants will continue to receive TAU following the active intervention period.
Study NCT04101968 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PET scan
Description: 3 PET scans to analyze the dopamine metabolism, acetylcholine and tau protein deposition in the brain.
Study NCT04101968 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: neuroQWERTY
Description: Analysis of free-text typing in a computer and/or a touch-screen device.
Study NCT04177355 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CpG 1018
Description: Administered by IM injection
Study NCT04177355 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-LSQ
Description: Administered by IM injection
Study NCT04177355 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alum (Aluminum Hydroxide Suspension)
Description: Administered by IM injection
Study NCT04177355 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trimer 4571
Description: Administered by IM injection
Study NCT04155398 — intervention group
Intervention type: PROCEDURE
Intervention: EUS elastography
Description: A forward view radial echoendoscope or a forward oblique view linear echoendoscope would be used to perform focused luminal examination of varices and EUS elastography for measurement of liver stiffness and spleen stiffness.
Study NCT01068184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6553
Description: Single or multiple oral dose
Study NCT01068184 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single or multiple oral dose
Study NCT03547427 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basal insulin alone
Description: A study insulin pump containing lispro insulin will be programmed to deliver basal lispro insulin at according to the subject's normal basal profile. The carbohydrate ratio(s) and insulin sensitivity factor(s) will be programmed per the subject's usual home parameters.
Study NCT03547427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basal pramlintide and reduced basal insulin
Description: A study insulin pump containing pramlintide will be programmed to deliver pramlintide at 6:1 pramlintide:insulin ratio. Simultaneously, a study insulin pump containing lispro insulin will be programmed to deliver basal lispro insulin at \~25% reduced rate from the subject's normal basal profile. The carbohydrate ratio(s) and insulin sensitivity factor(s) will be programmed per the subject's usual home parameters.
Study NCT03547427 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CGM
Description: Subjects will be instructed to initiate a Continuous Glucose Monitor (CGM) session 2-3 days prior to both the experimental and control CRU admissions.
Study NCT01356069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SB-APP
Description: SB-APP, derived from Brief-Adlerian Psychodynamic Psychotherapy (B-APP) is a time-limited (40 weekly sessions) psychodynamic psychotherapy based on Alfred Adler's theory and delivered in sequential and repeatable modules.~SB-APP is focused specifically on four personality functioning levels (PFL). These are assessed by the therapists on the basis of symptoms, quality of interpersonal relationships, overall social behaviors, cognitive and emotional patterns, and defense mechanisms
Study NCT01356069 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual
Description: This treatment consisted in a combination of medication, unstructured psychological support focused on socio-relational impairment and rehabilitative interventions provided by nurses and educators.
Study NCT03547427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CGM
Description: Subjects will be instructed to initiate a Continuous Glucose Monitor (CGM) session 2-3 days prior to both the experimental and control CRU admissions.
Study NCT03547427 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen test
Description: Consumption of a standardized meal mixed with added 1.5 g liquid acetaminophen
Study NCT01555099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5423
Description: oral inhaled
Study NCT01555099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: oral inhaled
Study NCT01555099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral inhaled
Study NCT03547427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acetaminophen test
Description: Consumption of a standardized meal mixed with added 1.5 g liquid acetaminophen
Study NCT03759743 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LMT1-48
Description: capsules containing Probiotics
Study NCT03759743 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules that did not contain any probiotics
Study NCT02541565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02541565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT02541565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02541565 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02541565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT02541565 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT02541565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT03332758 — intervention group
Intervention type: PROCEDURE
Intervention: Pars plana vitrectomy
Description: Standard of care treatment for retinal detachment, macular hole, or epiretinal membrane.
Study NCT03332758 — intervention group
Intervention type: PROCEDURE
Intervention: External drainage
Description: Standard of care treatment for retinal detachment.
Study NCT02968225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Game
Description: The game involves viewing subtle nonverbal behaviors of game characters for the purpose of executing their own goal-directed behavior in the game related to solving various crimes. The learning involves interpreting nonverbal cues on the animated characters, such as pointing, head turns, eye gaze cues.
Study NCT02466516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL
Description: SEL tablet administered orally once daily
Study NCT02466516 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIM
Description: Simtuzumab (SIM) 125 mg/mL single-dose vials administered subcutaneously once weekly
Study NCT01332058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: 8 possible weeks of motivational interviewing sessions
Study NCT00720421 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AZD7325
Description: AZD7325 Placebo oral 2 capsules
Study NCT00720421 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lorazepam
Description: Lorazepam 1 mg oral 2 tablets
Study NCT00431275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-675,206
Description: CP-675,206 15 mg/kg iv single dose on Day 1
Study NCT01181271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan (conditioning for AUTO transplant)
Description: 0.8 mg/kg intravenous (IV) bolus every six hours (Q6H) on days -8,-7,-6,-5 (total of 14 doses). The total daily dose of busulfan will be 3.2 mg/kg on days -8,-7, and -6 and 1.6 mg/kg on day -5
Study NCT01181271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide (conditioning for AUTO transplant)
Description: Etoposide 30 mg/kg IV bolus every day (QD) on day -4. The total daily dose of etoposide will be 30 mg/kg.
Study NCT01181271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (conditioning for AUTO transplant)
Description: Cyclophosphamide 60 mg/kg IV bolus QD on days -3 and -2. The total daily dose of cyclophosphamide will be 60 mg/kg.
Study NCT01181271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna (prior to AUTO transplant)
Description: Mesna 15 mg/kg IV bolus on days -3 and -2 infused over 15 minutes and given 15 minutes prior to cyclophosphamide administration. This is followed by Mesna given 15 mg/kg IV bolus three times daily (TID) on days -3 and -2 infused over 15 minutes at 3, 6, and 9 hours after completion of cyclophosphamide infusion. Total daily dose of Mesna should be equivalent to daily dose of cyclophosphamide. Lastly, Mesna will be given at 15 mg/kg IV bolus QD on day -1. This makes a total of 9 doses of Mesna
Study NCT01181271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autologous (auto) peripheral blood stem cell transplantation
Description: Infusion of autologous peripheral blood stem cells on Day 0.
Study NCT01181271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neupogen
Description: Neupogen 5 mcg/kg subcutaneous (SQ) daily starting on day +1 until absolute neutrophil count (ANC) is greater than or equal to 1000 per micro liter on two separate occasions or greater than 5000 per micro liter once
Study NCT01181271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine (conditioning for ALLO Transplant)
Description: Fludarabine 30 mg/m2/day will be administered as a bolus infusion over approximately 30 minutes for 4 days on days -5, -4, -3, -2.
Study NCT01181271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan (conditioning for ALLO Transplant)
Description: Busulfan will be administered by IV infusion over approximately 3 hours on days -5, -4, -3, -2. The dose of busulfan will be 0.8 mg/kg/day
Study NCT01181271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-myeloablative allogeneic (allo) transplant
Description: Donor peripheral blood stem cells (PBSC) will be infused intravenously beginning on Day 0. The minimum total CD34+ cell dose will be 2 x 10\^6 CD34+cells/kg of recipient's actual body weight with a maximum dose of 8 x 10\^6/kg of recipient's actual body weight
Study NCT01181271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus (FK506) will be given orally at a dose of 0.05 mg/kg orally (PO) twice a day (BID) starting day -3.
Study NCT01181271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus (rapamycin) will be given orally at a dose of 12 mg times one on day -3 and then the dose shall be 4 mg by mouth daily starting on day -2. The dose may then be adjusted according to serum levels at the discretion of the treating physician
Study NCT01181271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be administered once daily on days 1, 3, and 6 as an IV bolus over 15 minutes at a dose of 5 mg/m2
Study NCT02902718 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mē
Description: The mē device will be used for self administered facial treatments that will be repeated up to 3 times every session. The duration of a treatment session is 5-10 minutes.
Study NCT03827616 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated IMRT using helical Tomotherapy.
Description: 70 Gy in 28 fractions intensity-modulated radiotherapy (IMRT)
Study NCT03827616 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated IMRT using helical Tomotherapy.
Description: 60 Gy in 20 fractions intensity-modulated radiotherapy (IMRT) using helical Tomotherapy.
Study NCT02759770 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: This is a clinical observational study, no intervention was included.
Study NCT00720421 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lorazepam
Description: Lorazepam Placebo oral 2 tablets
Study NCT04414696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: eHealth exercise intervention for postpartum women at increased risk of depression
Study NCT03671382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication Training Program and Patient Prompt Sheet
Description: The intervention being delivered is a two-component intervent. First component is the Oncologist Communication Skills Training Program. This is an e-learning module teaching oncologists to recognize and respond to patient/caregiver distress, provide information including prognosis and discuss goals of care. The second component is a patient prompt sheet which will be administered to three patients of intervention arm oncologists in the waiting area at least 30 minutes before their consultation. The sheet includes structured questions for patients to ask the oncologist about diagnosis and prognosis and will prompt patients to label and express their emotions in a direct manner.
Study NCT03125876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT053PTSA
Description: receive oral CT053PTSA once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
Study NCT01478399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB1023 Injection
Description: 90 mg Dose
Study NCT02262234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Program Type 1
Description: The first part of the education program involves four weeks of in-person classes (2 hours per class) given once per week with homework assignments of approximately 30 minutes per day for at least 5 days per week. The second part of the education program involves home-based activities only, performed approximately 30 minutes per day for at least 5 days per week.